Journal of Virology & Antiviral ResearchISSN: 2324-8955

All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.

Implications for Hepatitis C Treatment and Disease Progression in an HIV/HCV Co-Infected Population

Implications for Hepatitis C Treatment and Disease Progression in an HIV/HCV Co-Infected Population

Morbidity and mortality rates from chronic liver disease secondary to hepatitis C virus (HCV) have become a significant issue for HIV infected patients. U.S. Department of Health and Human Service guidelines recommend HCV treatment for all coinfected patients without decompensated liver disease. Telaprevir and boceprevir are direct-acting agents (DAAs) recently approved for HCV genotype-1 mono-infection and have demonstrated marked improvements in viral suppression when combined with peg-interferon/ribavirin as triple therapy. Identification of co-infected patients who could benefit from HCV treatment is a necessary component of quality HIV care.

Special Features

Full Text

View

Track Your Manuscript

Media Partners

GET THE APP